微小核酸-29c於乳癌、子宮頸癌、子宮內膜癌和卵巢癌之預後價值

Prognostic Value of MiR-29c in Breast, Cervical, Endometrial, and Ovarian Cancer

乳癌(BC)和婦科癌包括子宮頸癌(CC),子宮內膜癌(EC)和卵巢癌 (OC)是全球主要的死亡原因。在台灣,乳癌和婦科癌症是女性罹患癌症的最高 死亡率。微小核酸(miR)-29c 已知具有腫瘤調節作用。但是,miR-29c 在乳腺 癌和婦科癌症中的預後價值仍然不確定。在這項研究中,我們存取 UALCAN 以進 行《癌症基因組圖譜》(TCGA)數據挖掘,確定 miR-29c 表達水平是否可以用作 預測標記。研究調查 miR-29c 的表達水平,分析高表達和低表達 miR-29c 的患者 組之間的生存分析。miR-29c 表達在正常和 BC 腫瘤組織之間無統計學差異。帶有 HER2 陽性和三陰性的 BC(TNBC)的 miR-29c 表達水平低於管腔亞型。攜帶低表 達 miR-29c 的 BC 患者比那些高表達 miR-29c 的患者俱有更短的生存時間。miR-29c 表達在正常和 CC 腫瘤組織之間無統計學差異。第四期 CC 組織的 miR-29c 表達水 平低於第三期 CC 組織。值得注意的是,具有低表達 miR-29c 的 CC 患者的生存時 間短於具有高表達 miR-29c 的 CC 患者。關於 EC,miR-29c 表達在正常和 EC 腫瘤 組織之間表現出統計學差異。青年時期的 EC 組織顯示出比老年時期更高的 miR-29c 表達值。此外,與那些高表達 miR-29c 的 EC 患者相比,那些低表達 miR-29c 的 EC 患者的生存時間縮短。有趣的是,子宮癌惡性肉瘤(UCS)則是在較老患者表現量 高於年輕者,且 miR-29c 高表達量預測生存時間縮短。在 OC 中,年齡最大的人 群的 miR-29a 表達水平低於年輕人組。miR-29c 的低表達表明存活率低。我們得出 的結論是,低表達 miR-29c 可以預測 BC,CC,EC 和 OC 患者的不良生存率,在 UCS 則是高表達 miR-29c。

 

Breast cancer (BC) and gynecological cancers including cervical cancer (CC), endometrial cancer (EC), uterine carcinosarcomas (UCS), and ovarian cancer (OC) are a leading cause of death globally. In Taiwan, breast cancer and gynecological cancers account for the highest mortality in women suffering from cancer. The tumor- regulatory role of microRNA (miR)-29c has been reported. However, the prognostic value of miR-29c in breast cancer and gynecological cancers remains uncertain. In this study, we performed Cancer Genome Atlas (TCGA) data-mining via UALCAN to determine whether miR-29c expression levels can serve as a predictive marker. Expression levels of miR-29c were surveyed. Survival analysis between patient groups harboring high and low expression of miR-29c were analyzed. miR-29c expression showed no statistical difference between normal and BC tumor tissue. BC with HER2-positive and triple negative (TNBC) showed lower miR-29c expression levels than that of the luminal subtype. BC patients harboring low expression of miR-29c demonstrated shorter survival time than those with high expression of miR-29c. miR-29c expression showed no statistical difference between normal and CC tumor tissue. CC tissue of stage 4 had lower miR-29c expression levels than that of stage 3. Notably, CC patients harboring low expression of miR-29c demonstrated shorter survival time than those with high expression of miR-29c. With regard to EC, miR-29c expression exhibited a statistical difference between normal and EC tumor tissue. EC tissue from young aged patients showed higher value of miR-29c expression than that in older aged patients. Furthermore, EC patients harboring low expression of miR-29c presented reduced survival time as compared those harboring high expression of miR- 29c. Interestingly, we noted that another type of uterus cancer, uterine carcinosarcomas (UCS), expressed higher miR-29c levels in older aged patients and miR-29c high expression predicted reduced survival time.
In OC, miR-29a expression levels of the oldest cohort were lower than those of young groups. Low expression of miR-29c indicated poor survival rate. We conclude that low expression of miR-29c can predict poor survival rate in patients with BC, CC, EC, UCS, and OC.